GT
KYMR icon

Glenmede Trust’s Kymera Therapeutics KYMR Stock Holding History

Glenmede Trust’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$848K Buy
7,394
+615
+9% +$52.8K ﹤0.01% 829
2026
Q1 		$565K Buy
6,779
+235
+4% +$18.6K ﹤0.01% 921
2025
Q4 		$509K Buy
+6,544
New +$442K ﹤0.01% 938
2021
Q3 		– Sell
-5,000
Closed -$242K – 1316
2021
Q2 		$242K Buy
+5,000
New +$217K ﹤0.01% 1090

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Glenmede Trust's KYMR Position: Q2 2026 in Review

Glenmede Trust increased its Kymera Therapeutics (KYMR) stake by 9.1% in Q2 2026, buying an estimated $52.8K and bringing the position to 7,394 shares worth $848K. The position accounts for ﹤0.01% of the portfolio, ranked #829.

Glenmede Trust first reported a position in KYMR in Q2 2021 and has held it in 4 quarters since. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Glenmede Trust held 7,394 shares of Kymera Therapeutics worth $848K as of Q2 2026.
  • Glenmede Trust bought 615 Kymera Therapeutics shares in Q2 2026, an estimated $52.8K.
  • Kymera Therapeutics made up ﹤0.01% of Glenmede Trust's portfolio in Q2 2026, its #829 holding.
  • Glenmede Trust first reported a position in Kymera Therapeutics in Q2 2021 and has held it in 4 quarters since.
  • 276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.